Juno licenses IP from OncoTracker, Fred Hutchinson
Biomarker firm OncoTracker Inc. and the Fred Hutchinson Cancer Research Center have each granted Juno Therapeutics Inc. exclusive intellectual property rights related to the combination of gamma-secretase inhibitors (GSIs) with B-cell maturation antigen (BCMA)-directed engineered T-cells for the treatment of multiple myeloma.
- Gene Therapy, Cell Therapy
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.